Albert Bourla of Pfizer is the CNN Business CEO of the Year | CNN Business
A securities lawyer breaks down the Pfizer CEO stock sale
Pfizer CEO Says Companies Should Make Profit On Covid-19 Vaccines - Barron's
Pfizer, the EU, and disappearing ink – POLITICO
Pfizer CEO sold $5.6-million of stock on day of COVID-19 vaccine update - The Globe and Mail
Pfizer CEO joins pharma executives selling stock in rally - The Boston Globe
Pfizer CEO Defends His Drug Firm's Shares
Pfizer CEO sold $5.6 million in stock on day of COVID vaccine news
Pfizer CEO reveals growth plan as company faces up to $18 billion revenue hit
Pfizer CEO Bourla on R&D, Obesity Drugs, and Winning Back Investors | At Barron's - YouTube
Pfizer CEO Read to Step Aside at Year's End - WSJ
Pfizer Coronavirus Vaccine News Raises Questions About CEO's Stock Sales : NPR
Lucky Pfizer CEO Bourla cashes out $5.6M worth of stock—perfectly legally—as COVID-19 vaccine data lift market | Fierce Pharma
Pfizer Stock: Is PFE Stock A Sell After Two Years In Free Fall? Or Will Seagen Bolster Sales? | Investor's Business Daily
Pfizer CEO Albert Bourla Helped Save The World. Can He Save His Company's Stock?
Pfizer's answer to tumbling stock is focusing on crowded cancer drug market | The Seattle Times
Pfizer CEO Albert Bourla received $24.3 million in total compensation for 2021
Pfizer Stock Is Falling. Did Investors Misunderstand the Revenue Guidance? - Barron's
Pfizer CEO Joins Host of Executives at Covid-19 Vaccine Makers in Big Stock Sale - WSJ
Pfizer's stock heads for biggest drop in 15 years as guidance falls short of estimates - MarketWatch
/cloudfront-us-east-2.images.arcpublishing.com/reuters/2F5SEG3FQFMXNIMIR342XIICMA.jpg "Pfizer CEO tests positive for COVID for a second time | Reuters")
Pfizer CEO tests positive for COVID for a second time | Reuters
Pfizer's Covid Boost Crashes to Earth - WSJ
Pfizer CEO: 'Disappointed' in presidential debate, vows no political pressure on Covid shot - POLITICO
Vaccine Capitalism: a run-down of the huge profits being made from COVID-19 vaccines - Corporate Watch
